Cancer Research PRL Inhibitor Induces the Cleavage of p130Cas  Sign up for Cancer Research eTOC's
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 51, 105-109, January 1, 1991]
© 1991 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fuqua, S. A. W.
Right arrow Articles by McGuire, W. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fuqua, S. A. W.
Right arrow Articles by McGuire, W. L.

Variant Human Breast Tumor Estrogen Receptor with Constitutive Transcriptional Activity1

Suzanne A. W. Fuqua, Saundra D. Fitzgerald, Gary C. Chamness, Atul K. Tandon, Donald P. McDonnell, Zafar Nawaz, Bert W. O'Malley and William L. McGuire2

University of Texas Health Science Center, Department of Medical Oncology, San Antonio, Texas 78284-7884 [S. A. W. F., S. D. F., G. C. C., A. K. T., W. L. M.], and Baylor College of Medicine, Houston, Texas 77030 [D. P. M., Z. N., B. W. O.]

Since progesterone receptor (PgR) is normally induced by estrogen, breast cancers lacking estrogen receptor (ER) would also be expected to lack PgR. However, a small percentage of breast cancers are ER- yet PgR+. These tumors might possess an ER which is defective in estrogen binding but is still functional in stimulating estrogen-responsive genes such as PgR. We have now detected such a variant, lacking exon 5 of the hormone-binding domain, using complementary DNA amplified by the polymerase chain reaction. This variant was the predominate ER RNA expressed in three ER-/PgR+ tumors. Furthermore, the variant ER constitutively activates transcription of a normally estrogen-dependent gene construct in yeast cells. The variant ER could explain the expression of PgR in certain tumors and have therapeutic implications.

1 Supported by an American Cancer Society Institutional Grant and NIH grant CA52351-01 to S. A. W. F. and NIH Grant CA30195 to W. L. M., who is a Clinical Research Professor of the American Cancer Society.

2 To whom requests for reprints should be addressed, at Department of Medicine/Oncology, University of Texas Health Science Center, 7703 Floyd Curl Dr., San Antonio, TX 78284-7884.

Received 7/ 9/90. Accepted 9/25/90.




This article has been cited by other articles:


Home page
Hum Mol GenetHome page
A. M. Dunning, C. S. Healey, C. Baynes, A.-T. Maia, S. Scollen, A. Vega, R. Rodriguez, N. L. Barbosa-Morais, B. A.J. Ponder, for SEARCH, et al.
Association of ESR1 gene tagging SNPs with breast cancer risk
Hum. Mol. Genet., March 15, 2009; 18(6): 1131 - 1139.
[Abstract] [Full Text] [PDF]


Home page
J Mol EndocrinolHome page
J. S Lewis, T J Thomas, R. G Pestell, C. Albanese, M. A Gallo, and T. Thomas
Differential effects of 16{alpha}-hydroxyestrone and 2-methoxyestradiol on cyclin D1 involving the transcription factor ATF-2 in MCF-7 breast cancer cells
J. Mol. Endocrinol., February 1, 2005; 34(1): 91 - 105.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
W. Bryant, A. E. Snowhite, L. W. Rice, and M. A. Shupnik
The Estrogen Receptor (ER){alpha} Variant {Delta}5 Exhibits Dominant Positive Activity on ER-Regulated Promoters in Endometrial Carcinoma Cells
Endocrinology, February 1, 2005; 146(2): 751 - 759.
[Abstract] [Full Text] [PDF]


Home page
Endocr. Rev.Home page
M. H. Herynk and S. A. W. Fuqua
Estrogen Receptor Mutations in Human Disease
Endocr. Rev., December 1, 2004; 25(6): 869 - 898.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
V.-J. Bardou, G. Arpino, R. M. Elledge, C. K. Osborne, and G. M. Clark
Progesterone Receptor Status Significantly Improves Outcome Prediction Over Estrogen Receptor Status Alone for Adjuvant Endocrine Therapy in Two Large Breast Cancer Databases
J. Clin. Oncol., May 15, 2003; 21(10): 1973 - 1979.
[Abstract] [Full Text] [PDF]


Home page
JNCI J Natl Cancer InstHome page
G. Konecny, G. Pauletti, M. Pegram, M. Untch, S. Dandekar, Z. Aguilar, C. Wilson, H.-M. Rong, I. Bauerfeind, M. Felber, et al.
Quantitative Association Between HER-2/neu and Steroid Hormone Receptors in Hormone Receptor-Positive Primary Breast Cancer
J Natl Cancer Inst, January 15, 2003; 95(2): 142 - 153.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
T. Bachleitner-Hofmann, B. Pichler-Gebhard, M. Rudas, M. Gnant, S. Taucher, D. Kandioler, E. Janschek, P. Dubsky, S. Roka, E. Sporn, et al.
Pattern of Hormone Receptor Status of Secondary Contralateral Breast Cancers in Patients Receiving Adjuvant Tamoxifen
Clin. Cancer Res., November 1, 2002; 8(11): 3427 - 3432.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
P. T. K. Saunders, M. R. Millar, S. Macpherson, D. S. Irvine, N. P. Groome, L. R. Evans, R. M. Sharpe, and G. A. Scobie
ER{beta}1 and the ER{beta}2 Splice Variant (ER{beta}cx/{beta}2) Are Expressed in Distinct Cell Populations in the Adult Human Testis
J. Clin. Endocrinol. Metab., June 1, 2002; 87(6): 2706 - 2715.
[Abstract] [Full Text] [PDF]


Home page
Biol. Reprod.Home page
H. A. LaVoie, D. C. DeSimone, C. Gillio-Meina, and Y. Y. Hui
Cloning and Characterization of Porcine Ovarian Estrogen Receptor {beta} Isoforms
Biol Reprod, March 1, 2002; 66(3): 616 - 623.
[Abstract] [Full Text] [PDF]


Home page
Mol. Endocrinol.Home page
M.-C. Zennaro, A. Souque, S. Viengchareun, E. Poisson, and M. Lombes
A New Human MR Splice Variant Is a Ligand-Independent Transactivator Modulating Corticosteroid Action
Mol. Endocrinol., September 1, 2001; 15(9): 1586 - 1598.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
R. A. McClelland, D. Barrow, T.-A. Madden, C. M. Dutkowski, J. Pamment, J. M. Knowlden, J. M. W. Gee, and R. I. Nicholson
Enhanced Epidermal Growth Factor Receptor Signaling in MCF7 Breast Cancer Cells after Long-Term Culture in the Presence of the Pure Antiestrogen ICI 182,780 (Faslodex)
Endocrinology, July 1, 2001; 142(7): 2776 - 2788.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
W. F. Anderson, K. C. Chu, N. Chatterjee, O. Brawley, and L. A. Brinton
Tumor Variants by Hormone Receptor Expression in White Patients With Node-Negative Breast Cancer From the Surveillance, Epidemiology, and End Results Database
J. Clin. Oncol., January 1, 2001; 19(1): 18 - 27.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
S. A. W. Fuqua, C. Wiltschke, Q. X. Zhang, A. Borg, C. G. Castles, W. E. Friedrichs, T. Hopp, S. Hilsenbeck, S. Mohsin, P. O’Connell, et al.
A Hypersensitive Estrogen Receptor-{{alpha}} Mutation in Premalignant Breast Lesions
Cancer Res., August 1, 2000; 60(15): 4026 - 4029.
[Abstract] [Full Text]


Home page
Mol. Endocrinol.Home page
A. Bollig and R. J. Miksicek
An Estrogen Receptor-{alpha} Splicing Variant Mediates Both Positive and Negative Effects on Gene Transcription
Mol. Endocrinol., May 1, 2000; 14(5): 634 - 649.
[Abstract] [Full Text]


Home page
J. Clin. Endocrinol. Metab.Home page
V. Speirs, I. P. Adams, D. S. Walton, and S. L. Atkin
Identification of Wild-Type and Exon 5 Deletion Variants of Estrogen Receptor {beta} in Normal Human Mammary Gland
J. Clin. Endocrinol. Metab., April 1, 2000; 85(4): 1601 - 1605.
[Abstract] [Full Text]


Home page
J. Biol. Chem.Home page
E. M. Resnick, D. A. Schreihofer, A. Periasamy, and M. A. Shupnik
Truncated Estrogen Receptor Product-1 Suppresses Estrogen Receptor Transactivation by Dimerization with Estrogen Receptors alpha and beta
J. Biol. Chem., March 15, 2000; 275(10): 7158 - 7166.
[Abstract] [Full Text] [PDF]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
S. A. Khan, A. Sachdeva, S. Naim, M. M. Meguid, W. Marx, H. Simon, J. D. Halverson, and P. J. Numann
The Normal Breast Epithelium of Women with Breast Cancer Displays an Aberrant Response to Estradiol
Cancer Epidemiol. Biomarkers Prev., October 1, 1999; 8(10): 867 - 872.
[Abstract] [Full Text]


Home page
Mol. Endocrinol.Home page
Y. Lavrovsky, R. K. Tyagi, S. Chen, C. S. Song, B. Chatterjee, and A. K. Roy
Ribozyme-Mediated Cleavage of the Estrogen Receptor Messenger RNA and Inhibition of Receptor Function in Target Cells
Mol. Endocrinol., June 1, 1999; 13(6): 925 - 934.
[Abstract] [Full Text]


Home page
EndocrinologyHome page
C. Pasqualini, D. Guivarc’h, Y. v. Boxberg, F. Nothias, J.-D. Vincent, and P. Vernier
Stage- and Region-Specific Expression of Estrogen Receptor {alpha} Isoforms during Ontogeny of the Pituitary Gland
Endocrinology, June 1, 1999; 140(6): 2781 - 2789.
[Abstract] [Full Text]


Home page
CirculationHome page
Y. K. Hodges, J. K. Richer, K. B. Horwitz, and L. D. Horwitz
Variant Estrogen and Progesterone Receptor Messages in Human Vascular Smooth Muscle
Circulation, May 25, 1999; 99(20): 2688 - 2693.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
R. L. Balleine, S. M. N. Hunt, and C. L. Clarke
Coexpression of Alternatively Spliced Estrogen and Progesterone Receptor Transcripts in Human Breast Cancer
J. Clin. Endocrinol. Metab., April 1, 1999; 84(4): 1370 - 1377.
[Abstract] [Full Text]


Home page
JNCI J Natl Cancer InstHome page
S. G. Hilsenbeck, W. E. Friedrichs, R. Schiff, P. O'Connell, R. K. Hansen, C. K. Osborne, and S. A. W. Fuqua
Statistical Analysis of Array Expression Data as Applied to the Problem of Tamoxifen Resistance
J Natl Cancer Inst, March 3, 1999; 91(5): 453 - 459.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
E. Leygue, H. Dotzlaw, P. H. Watson, and L. C. Murphy
Expression of Estrogen Receptor {beta}1, {beta}2, and {beta}5 Messenger RNAs in Human Breast Tissue
Cancer Res., March 1, 1999; 59(6): 1175 - 1179.
[Abstract] [Full Text] [PDF]


Home page
Mol. Endocrinol.Home page
G. A. Peters and S. A. Khan
Estrogen Receptor Domains E and F: Role in Dimerization and Interaction with Coactivator RIP-140
Mol. Endocrinol., February 1, 1999; 13(2): 286 - 296.
[Abstract] [Full Text]


Home page
J. Clin. Endocrinol. Metab.Home page
M. A. Shupnik, L. K. Pitt, A. Y. Soh, A. Anderson, M. B. Lopes, and E. R. Laws Jr.
Selective Expression of Estrogen Receptor {alpha} and {beta} Isoforms in Human Pituitary Tumors
J. Clin. Endocrinol. Metab., November 1, 1998; 83(11): 3965 - 3972.
[Abstract] [Full Text]


Home page
Mol. Endocrinol.Home page
S. S. Chaidarun and J. M. Alexander
A Tumor-Specific Truncated Estrogen Receptor Splice Variant Enhances Estrogen-Stimulated Gene Expression
Mol. Endocrinol., September 1, 1998; 12(9): 1355 - 1366.
[Abstract] [Full Text]


Home page
Pharmacol. Rev.Home page
J. I. Macgregor and V. C. Jordan
Basic Guide to the Mechanisms of Antiestrogen Action
Pharmacol. Rev., June 1, 1998; 50(2): 151 - 196.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
V. Budhram-Mahadeo, M. Parker, and D. S. Latchman
POU Transcription Factors Brn-3a and Brn-3b Interact with the Estrogen Receptor and Differentially Regulate Transcriptional Activity via an Estrogen Response Element
Mol. Cell. Biol., February 1, 1998; 18(2): 1029 - 1041.
[Abstract] [Full Text]


Home page
GutHome page
I Shimizu, M Yasuda, Y Mizobuchi, Y-R Ma, F Liu, M Shiba, T Horie, and S Ito
Suppressive effect of oestradiol on chemical hepatocarcinogenesis in rats
Gut, January 1, 1998; 42(1): 112 - 119.
[Abstract] [Full Text] [PDF]


Home page
Mol. Endocrinol.Home page
I. Erenburg, B. Schachter, R. M. y Lopez, and L. Ossowski
Loss of an Estrogen Receptor Isoform (ER{alpha}{Delta}3) in Breast Cancer and the Consequences of Its Reexpression: Interference with Estrogen-Stimulated Properties of Malignant Transformation
Mol. Endocrinol., December 1, 1997; 11(13): 2004 - 2015.
[Abstract] [Full Text] [PDF]


Home page
Mol. Endocrinol.Home page
W. Porter, B. Saville, D. Hoivik, and S. Safe
Functional Synergy between the Transcription Factor Sp1 and the Estrogen Receptor
Mol. Endocrinol., October 1, 1997; 11(11): 1569 - 1580.
[Abstract] [Full Text]


Home page
J. Clin. Endocrinol. Metab.Home page
S. S. Chaidarun, A. Klibanski, and J. M. Alexander
Tumor-Specific Expression of Alternatively Spliced Estrogen Receptor Messenger Ribonucleic Acid Variants in Human Pituitary Adenomas
J. Clin. Endocrinol. Metab., April 1, 1997; 82(4): 1058 - 1065.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
M. Perrot-Applanat, K. Cohen-Solal, E. Milgrom, and M. Finet
Progesterone Receptor Expression in Human Saphenous Veins
Circulation, November 15, 1995; 92(10): 2975 - 2983.
[Abstract] [Full Text]


Home page
J. Biol. Chem.Home page
M. B. Martin, P. Garcia-Morales, A. Stoica, H. B. Solomon, M. Pierce, D. Katz, S. Zhang, M. Danielsen, and M. Saceda
Effects of 12-O-Tetradecanoylphorbol-13-acetate on Estrogen Receptor Activity in MCF-7 Cells
J. Biol. Chem., October 20, 1995; 270(42): 25244 - 25251.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1991 by the American Association for Cancer Research.